Executive Team

Cameron is an experienced entrepreneurial executive, with expertise in biotechnology companies. He has extensive experience in the management, structuring, and strategic planning of start-up companies and has held positions including Chief Executive Officer, Chief Financial Officer, and Non-Executive Director of public and private enterprises.

Cameron was educated at the University of Western Australia receiving both a Bachelor of Commerce and an MBA.

Jake is an experienced scientist with expertise in research and development and in the management of early stage biotechnical companies, including the manufacturing of biotechnology products and the establishment of manufacturing operations. Jake received his BSc in Biology and Chemistry, and his PhD in Physical Chemistry from King’s College London. In addition, he received his MSc in Chemical Pathology from St Thomas’ Hospital Medical School, and his MBA from Imperial College Management School.

Mr. Hughes is a seasoned finance professional with over twenty-five years of accounting, finance and business management experience gained through an international career spanning the United States, Europe and Asia and joins Volition from AUM Biosciences Pte. Ltd., a fast-growing biotechnology company focused on developing novel cancer drugs, where he acted as Chief Financial Officer since 2018. Prior to then, Mr. Hughes held a number of senior leadership positions at Elsevier, a division of RELX Group plc, a FTSE 100 company, including regional Managing Director and regional Finance Director for Elsevier Health Solutions. He has extensive experience in financial reporting, planning & analysis, and profit and loss management, as well as product commercialization, licensing and distributor management.

Mr. Hughes holds a Bachelor's degree in Accounting and Law from De Montfort University, Leicester, UK.

Dr. Gaetan Michel has been with Volition almost seven years, previously serving as Chief Operating Officer of Belgian Volition and currently as Chief Executive Officer of Belgian Volition. With over 15 years of project management, manufacturing and operational experience, Dr. Michel is ideally placed to oversee and expand Volition's global operations including the newly opened Innovation Hub in San Diego, the manufacturing facility "Silver One" and Research and Development Facility in Belgium, as well as expanding the veterinary subsidiary in Texas, U.S.A.

Mr. Gael Forterre has over 15 years of experience investing in and scaling fast growing companies. Mr. Forterre started his career as a hedge fund analyst in Paris and worked in a number of investment banking and trading roles over ten plus years, including launching Armori Capital Management LLC in 2014, for which he conducted a large number of investments on behalf of family offices/institutional investors and became active in supporting the growth of its portfolio companies. Most recently, from 2017 until joining Volition, he served as the Chief Executive Officer of Ucroo Incorporated, a fast-growing collaboration and communication technology company, which he led to a tripling in revenue growth two years in a row. Mr. Forterre continues to serve as a board member of Ucroo Incorporated and Article22.

Mr. Forterre holds a Master's degree in finance from Sorbonne Paris I and a double MBA from Columbia Business School and the London Business School.

Dr. Mark Eccleston, one of Volition's founding scientists will now serve as our new Chief Technology Officer. Dr. Eccleston has over 20 years' experience in the biotechnology sector and holds a PhD in Polymer Chemistry for biomedical applications. In this new role, he will identify and review new and innovative infrastructures which will aid in the deployment of Volition's proprietary Nu.Q™ platform.

Louise brings more than 20 years of marketing, sales and leadership experience to her role at Volition. Since 2011, she has served as Director and Owner of Aculd Ltd, a strategic marketing consultancy specializing in healthcare. Formerly Louise worked in various roles at Reckitt Benckiser including some overseas posts in Paris and New York. She holds a Bachelor of Arts in Business Studies from Sheffield Hallam University.

Gaetan has over 10 years of experience in production management. Following the completion of his PhD in 2002, Gaetan joined AAT (Advanced Array Technology), a University of Namur spin-off company as project manager in proteomics. AAT later became EAT (Eppendorf Array Technology), part of the German Eppendorf Biotech company, where Gaetan became production manager and was involved in establishing production processes and equipment. From 2007 to 2010 he worked for KitoZyme, a global manufacturer of biopolymers of fungal origin with its core business in weight management, digestive and cardiovascular health.

Jason has expertise in clinical medicine and in laboratory diagnostics. He was educated at Hardin-Simmon University (Biochemistry) where he graduated Summa Cum Laude, also receiving the Holland Medal of Honor. He received his Doctor of Medicine from the University of Texas Medical School at Houston and affiliate MD Anderson Cancer Center.

Jason has a strong grounding in both medicine and more specifically in diagnostics and product commercialization.

Jasmine has a proven track record in achieving positive business results by developing strategic business alliances, identifying new markets, and developing business processes. As a thought leade in technology management and commercialization, she has worked with numerous health and regulatory bodies across Asia and has successfully comercialised technologies and expanded companies into the Asian markets.

Jasmine has a Bachelor of Engineering and a Doctor of Philosophy in Oceanography from the National University of Singapore.

Mr. Dewsbury has global expertise in the animal health industry having direct involvement in national testing programs, current health diagnostics platforms and commercializing next generation diagnostics. He has a strong background in forming new commercial teams as well as launching and growing successful animal focused startups, all to achieve a global impact on the lives of animals. Mr. Dewsbury was educated at Texas A&M University where he received both his science and business degrees.

Rod is an experienced legal and corporate secretary with over ten years’ experience in providing corporate, legal and administrative services to start-up companies. He previously served as corporate secretary for several junior mining companies in the United Kingdom. Rod received a Bachelor of Laws degree from the University of Western Australia.

Scott has nearly 20 years of experience in the U.S. capital markets and investor relations. Scott has served as Head of Investor Relations for four public companies, including Volition, and worked for several years as an investment banker. He earned his B.S. in Business Administration from Bryant University and his MA and PhD degrees from Brown University.

Dr Mark Eccleston is an enthusiastic and passionate biotechnology entrepreneur with over 20 years experience in the sector. He holds a PhD in Polymer Chemistry for biomedical applications and gained an MBA (entrepreneurship) from the University of Dundee in 2008.

Mark is the Managing Director of OncoLytika Ltd. a technical consultancy company working with international private and public limited companies operating in the diagnostics and therapeutic sectors as well as academia.

Dr Eccleston is the Business Development Director at Volition, a company developing next generation blood tests for early detection of cancer. Volition’s epigenetics based immunoassay approach to rapid, affordable cancer diagnostics is intended to revolutionise cancer screening and diagnosis. Mark coordinates the commercialisation of Volition’s Research Use kit range based on this proprietary Nucleosomics® technology platform.